J Breast Cancer.  2010 Sep;13(3):237-241.

Hormone Replacement Therapy and Breast Cancer: The Situation in Korea

• Lee JB
• Kim LS

Abstract

No abstract available.

MeSH Terms

Breast
Hormone Replacement Therapy
Korea

Figure

• 

  Figure 1 Relative risk of incident invasive breast cancer in relation to recency and type of HRT used. FCI=floated CI. *Relative to never users of HRT, stratified by age, time since menopause, parity and age at first birth, family history of breast cancer, body-mass index, region, and deprivation index (From Beral V, et al. Lancet 2003;362:419-27, with permission from Elsevier).(17)

• 

  Figure 2 Relative risk of invasive breast cancer in relation to recency, total duration of use, and type of HRT used at baseline. FCI=floated CI. *Relative to never users of HRT, stratified by age, time since menopause, parity and age at first birth, family history of breast cancer, body-mass index, region, and deprivation index (From Beral V, et al. Lancet 2003;362: 419-27, with permission from Elsevier).(17)

Reference

1. Skouby SO, Al-Azzawi F, Barlow D, Calaf-Alsina Erdogan Ertüngealp J, Gompel A, Graziottin A, et al. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy. Maturitas. 2005. 51:8–14.

2. Kronenberg F. Hot flashes: epidemiology and physiology. Ann N Y Acad Sci. 1990. 592:52–86.

3. Schneider H. Kato J, Minaguchi H, Nishino Y, editors. General aspects of world-wide HRT. Hormone Replacement Therapy and Osteoporosis. 2000. Berlin/New York: Springer;1–28.

4. Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med. 2001. 344:276–285.

5. Key T, Appleby P, Barnes I, Reeves G. Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002. 94:606–616.

6. Bernstein L, Ross RK. Endogenous hormones and breast cancer risk. Epidemiol Rev. 1993. 15:48–65.

7. Clarke M. Ovarian ablation in breast cancer, 1896 to 1998: milestones along hierarchy of evidence from case report to Cochrane review. Br Med J. 1998. 317:1246–1248.

8. Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation for early breast cancer: overview of the randomized trials. Lancet. 1996. 348:1189–1196.

9. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet. 1997. 350:1047–1059.

10. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 2005. 97:1652–1662.

11. Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, Shore RE, Koenig KL, Banerjee S, et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst. 1995. 87:190–197.

12. Thomas HV, Key TJ, Allen DS, Moore JW, Dowsett M, Fentiman IS, et al. A prospective study of endogenous serum hormone concentrations and breast cancer risk in postmenopausal women on the island of Guernsey. Br J Cancer. 1997. 76:401–405.

13. Cauley JA, Lucas FL, Kuller LH, Stone K, Browner W, Cummings SR. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Ann Intern Med. 1999. 130:270–277.

14. Liehr JG. Is estradiol a genotoxic mutagenic carcinogen? Endocr Rev. 2000. 21:40–54.

15. Kenemans P, Bosman A. Breast cancer and post-menopausal hormone therapy. Best Pract Res Clin Endocrinol Metab. 2003. 17:123–137.

16. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002. 288:321–333.

17. Beral V. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003. 362:419–427.

18. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA. 2003. 289:3243–3253.

19. Prentice RL, Chlebowski RT, Stefanick ML, Manson JE, Langer RD, Pettinger M, et al. Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. Am J Epidemiol. 2008. 167:1407–1415.

20. Tjønneland A, Christensen J, Thomsen BL, Olsen A, Overvad K, Ewertz M, et al. Hormone replacement therapy in relation to breast carcinoma incidence rate ratios: a prospective Danish cohort study. Cancer. 2004. 100:2328–2337.

21. Newcomb PA, Titus-Ernstoff L, Egan KM, Trentham-Dietz A, Baron JA, Storer BE, et al. Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2002. 11:593–600.

22. Banks E, Reeves G, Beral V, Bull D, Crossley B, Simmonds M, et al. Influence of personal characteristics of individual women on sensitivity and specificity of mammography in the Million Women Study. BMJ. 2004. 329:477.

23. Campagnoli C, Clavel-Chapelon F, Kaaks R, Peris C, Berrino F. Progestins and progesterone in hormone replacement therapy and the risk of breast cancer. J Steroid Biochem Mol Biol. 2005. 96:95–108.

24. Doren M, Reuther G, Minne HW, Schneider HP. Superior compliance and efficacy of continuous combined oral estrogen-progestogen replacement therapy in postmenopausal women. Am J Obstet Gynecol. 1995. 173:1446–1451.

25. Mccarty MF. Androgenic progestins amplify the breast cancer risk associated with hormone replacement therapy by boosting IGF-I activity. Med Hypotheses. 2001. 56:213–216.

26. Magnusson C, Baron JA, Correia N, Bergstrom R, Adami HO, Persson I. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer. 1999. 81:339–344.

27. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst. 2000. 92:328–332.

28. Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev. 1993. 15:17–15.

29. Banks E, Beral V, Reeves G. Million Women Study Collaborators. Published results on breast cancer and hormone replacement therapy in the Million Women Study are correct. Climacteric. 2004. 7:415–416.

30. Holmberg L, Anderson H. HABITS steering and data monitoring committees. HABITS (hormonal replacement therapy after breast cancer -- is it safe?), a randomized comparison: trial stopped. Lancet. 2004. 363:453–455.

31. MacLennan A, Broadbent J, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestagen therapy versus placebo for hot flushes. Cochrane Database Syst Rev. 2004. (4):CD002978.

32. Hendrix S, Cochrane B, Nygaard I, Handa VL, Barnabei VM, Iglesia C, et al. Effects of estrogen with and without progestin on urinary incontinence. JAMA. 2005. 293:935–948.

33. Simon JA, Hunninghake D, Agarwal SK, Lin F, Cauley JA, Ireland CC, et al. Effect of estrogen plus progestin on risk for biliary tract surgery in postmenopausal women with coronary artery disease. Ann Intern Med. 2001. 135:493–501.

34. Liu B, Beral V, Balkwill A, Green J, Sweetland S, Reeves G, et al. Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study. BMJ. 2008. 337:a386.

35. Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative Randomized Trial. JAMA. 2003. 290:1729–1738.

36. Breast Cancer Facts & Figures 2006-2008. 2010. June 9th. Korean Breast Cancer Society;http://www.kbcs.or.kr/journal/file/2006_2008_Breast_Cancer_Facts_and_Figures_updated.pdf.

37. Banks E, C Karen, Reeves G. HRT and breast cancer: recent findings in the context of the evidence to date. Womens Health (Lond Engl). 2008. 4:427–431.